Donald L. Siegel

University of Pennsylvania — United States

Medicine · Health Sciences

21h-index6.1kcitations124works10.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(110), Viral Infectious Diseases and Gene Expression in Insects(33), Immune Cell Function and Interaction(17), Biosimilars and Bioanalytical Methods(12), T-cell and B-cell Immunology(9)

Publications123 total

Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer
Cell Reports Medicine·2025· 2 citedOpen Access
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
Journal for ImmunoTherapy of Cancer·2025· 11 citedOpen Access
Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy
Cell stem cell·2024· 54 citedOpen Access
TMOD-02. PATIENT-DERIVED GLIOBLASTOMA ORGANOIDS AS REAL-TIME AVATARS FOR ASSESSING RESPONSES TO CLINICAL CAR-T CELL THERAPY
Neuro-Oncology·2024Open Access
Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy
2024· 5 citedOpen Access
Figure S5 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S7 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S3 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S4 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S9 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S8 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S6 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Table S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Table S3 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S11 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S4 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
Figure S7 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Joseph A. Fraietta(35), Noelle V. Frey(29), Gabriela Plesa(28), Elizabeth O. Hexner(27), David L. Porter(26), Frederic D. Bushman(26), In-Young Jung(23), Andrew J. Rech(22), Shelley L. Berger(22), Vivek Narayan(21), J.K. Everett(21), Naomi B. Haas(21), Robert L. Bartoszek(21), Sierra M. Collins(20), Erik F. Williams(20), Soon‐Keat Ooi(19), Caitlin R. Hopkins(19), Adrian Cantu(19), Sònia Guedan(19), Friederike Herbst(19)